Clinical Trials

87 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06281405 2026-04-03

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT07481058 2026-03-20

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

NSCLC

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07457359 2026-03-09

NEOTRIO-2

18 enrolled

Triple Negative Breast Neoplasms

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

268 enrolled

Head and Neck Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Small Cell Lung Carcinoma

NCT04918186 2026-02-12

IPROC

Gynecologic

Ovarian Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

30 enrolled

Oropharyngeal Neoplasms

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

111 enrolled

Breast Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

35 enrolled

Triple Negative Breast Neoplasms

NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

90 enrolled

Carcinoma, Transitional Cell

NCT06735131 2025-12-03

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Triple Negative Breast Neoplasms

NCT03926338 2025-11-20

PICC

270 enrolled

Turcot syndrome, Colorectal Neoplasms

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Neoplasms

NCT06623136 2025-09-26

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT07140679 2025-09-25

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Colonic Neoplasms

NCT07172386 2025-09-16

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

Carcinoma, Renal Cell

NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

276 enrolled

Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT06127303 2025-09-05

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06611813 2025-08-12

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

30 enrolled

Breast Neoplasms

NCT07039656 2025-08-07

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

211 enrolled

Stage IB-IIIB NSCLC

NCT07088211 2025-07-31

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

39 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07092696 2025-07-30

Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer

34 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

27 enrolled

Breast Neoplasms

NCT05147844 2025-07-14

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT06940180 2025-06-26

Toripalimab With Chemotherapy for Sinus Cancer

20 enrolled

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Paranasal Sinus Neoplasms

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Nasopharyngeal Carcinoma

NCT06964906 2025-05-11

NeoHunter

140 enrolled

Breast Neoplasms

NCT06415318 2025-04-22

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

25 enrolled

Penile Neoplasms

NCT06843889 2025-04-16

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

34 enrolled

Esophageal Neoplasms

NCT06878625 2025-03-25

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

138 enrolled

Triple Negative Breast Neoplasms

NCT06823427 2025-03-21

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Carcinoma, Transitional Cell

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Nasopharyngeal Carcinoma

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

46 enrolled

Locally Advanced Rectal Cancer

NCT06642545 2025-02-17

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Breast Neoplasms

NCT05033392 2025-02-05

PNACGEC

62 enrolled

Stomach Neoplasms

NCT06791070 2025-01-24

RC48&J for EPD

20 enrolled

Paget Disease, Extramammary

NCT05555888 2025-01-15

TORCH-E

34 enrolled

Early Low Rectal Cancer

NCT06020755 2024-12-31

TA7

17 enrolled

Gynecologic

Gestational Trophoblastic Disease

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

41 enrolled

Urinary Bladder Neoplasms

NCT06269211 2024-11-18

TOPLINE

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06690697 2024-11-15

Combination of Toripalimab and JS004 Therapy for ccRCC

80 enrolled

Carcinoma, Renal Cell

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT05963490 2024-09-24

SLOT

108 enrolled

Microsatellite Stable Metastatic Colorectal Cancer

NCT05715931 2024-09-19

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

30 enrolled